首页> 美国卫生研究院文献>Clinical Epigenetics >Identification of the epigenetic reader CBX2 as a potential drug target in advanced prostate cancer

【2h】

Identification of the epigenetic reader CBX2 as a potential drug target in advanced prostate cancer

机译：表观遗传阅读器CBX2鉴定为晚期前列腺癌的潜在药物靶标

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundWhile localized prostate cancer (PCa) can be effectively cured, metastatic disease inevitably progresses to a lethal state called castration-resistant prostate cancer (CRPC). Emerging evidence suggests that aberrant epigenetic repression by the polycomb group (PcG) complexes fuels PCa progression, providing novel therapeutic opportunities.

机译：背景技术虽然可以有效治愈局部前列腺癌（PCa），但转移性疾病不可避免地会发展成致命的状态，称为去势抵抗性前列腺癌（CRPC）。越来越多的证据表明，聚梳组（PcG）复合物对表观遗传的异常抑制作用促进了PCa的发展，提供了新的治疗机会。

著录项

期刊名称 Clinical Epigenetics
作者
Pier-Luc Clermont; Francesco Crea; Yan Ting Chiang; Dong Lin; Amy Zhang; James Z. L. Wang; Abhijit Parolia; Rebecca Wu; Hui Xue; Yuwei Wang; Jiarui Ding; Kelsie L. Thu; Wan L. Lam; Sohrab P. Shah; Colin C. Collins; Yuzhuo Wang; Cheryl D. Helgason;
展开▼
作者单位

展开▼
年(卷),期 2016(8),-1
年度 2016
页码 16
总页数 14
原文格式 PDF
正文语种
中图分类遗传学;
关键词
Castration-resistant prostate cancer CBX2 Epigenetics Metastatic prostate cancer Polycomb;

机译：去势抵抗性前列腺癌;CBX2;表观遗传学;转移性前列腺癌;Polycomb;

相似文献

外文文献
中文文献
专利

1. Identification of the epigenetic reader CBX2 as a potential drug target in advanced prostate cancer [J] . Pier-Luc Clermont, Francesco Crea, Yan Ting Chiang, Clinical epigenetics. . 2016,第1期

机译：表观遗传阅读器CBX2鉴定为晚期前列腺癌的潜在药物靶标
2. Epigenetics of prostate cancer and the prospect of identification of novel drug targets by RNAi screening of epigenetic enzymes [J] . BjrkmanM., RantalaJ., NeesM., Epigenomics . 2010,第5期

机译：前列腺癌的表观遗传学和通过表观遗传酶的RNAi筛选鉴定新型药物靶标的前景
3. Drug discovery targeting epigenetic codes: the great potential of UHRF1, which links DNA methylation and histone modifications, as a drug target in cancers and toxoplasmosis. [J] . Unoki M, Brunet J, Mousli M Biochemical Pharmacology . 2009,第10期

机译：针对表观遗传密码的药物发现：UHRF1具有巨大的潜力，可将DNA甲基化和组蛋白修饰联系起来，成为癌症和弓形虫病的药物靶标。
4. Drug Discovery Targeting PRC2 to Alter Epigenetics for Therapeutics of Triple Negative Breast Cancer [C] . Duxin Sun International Forum on Leading Edge Technologies on Crystallization Engineering and Pharmaceutics Development;Tianjin University;Tianjin Medical University . -1

机译：药物发现靶向PRC2以改变三重阴性乳腺癌治疗的表观遗传学
5. Improving cryosurgical ablation of advanced stage prostate cancer through identification of molecular targets in a prostate cancer cell model. [D] . Klossner, Daniel Patrick. 2007

机译：通过鉴定前列腺癌细胞模型中的分子靶标来改善晚期前列腺癌的冷冻消融。
6. Systematic Structure Modifications of Multi-target Prostate Cancer Drug Candidate Galeterone to Produce Novel Androgen Receptor Down-regulating Agents as an Approach to Treatment of Advanced Prostate Cancer [O] . Puranik Purushottamachar, Abhijit M. Godbole, Lalji K. Gediya, -1

机译：系统结构修饰的多靶点前列腺癌候选药物加勒泰酮生产新型雄激素受体下调剂作为晚期前列腺癌的治疗方法
7. Identification of the epigenetic reader CBX2 as a potential drug target in advanced prostate cancer [O] . 2016

机译：表观遗传阅读器CBX2鉴定为晚期前列腺癌的潜在药物靶标
8. Identification of Novel Drug Targets and Lead Compounds for Advanced Prostate Cancer through Genomic and Cheminformatic Analyses. [R] . Hsing, M. 2016

机译：通过基因组和化学分析鉴定新型前列腺癌药物靶标和先导化合物。

Identification of the epigenetic reader CBX2 as a potential drug target in advanced prostate cancer

摘要

著录项

相似文献

相关主题

期刊订阅